WO1990002186A1 - Production de proteines non structurales du virus de la fievre catarrhale (btv) faisant appel a un vecteur d'expression du baculovirus - Google Patents

Production de proteines non structurales du virus de la fievre catarrhale (btv) faisant appel a un vecteur d'expression du baculovirus Download PDF

Info

Publication number
WO1990002186A1
WO1990002186A1 PCT/GB1989/000939 GB8900939W WO9002186A1 WO 1990002186 A1 WO1990002186 A1 WO 1990002186A1 GB 8900939 W GB8900939 W GB 8900939W WO 9002186 A1 WO9002186 A1 WO 9002186A1
Authority
WO
WIPO (PCT)
Prior art keywords
btv
protein
polypeptide
cells
infected
Prior art date
Application number
PCT/GB1989/000939
Other languages
English (en)
Inventor
Polly Roy
Original Assignee
Polly Roy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polly Roy filed Critical Polly Roy
Publication of WO1990002186A1 publication Critical patent/WO1990002186A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to a process for producing bluetongue virus proteins.
  • Bluetongue virus is the prototype virus of the Qvbi ⁇ iTus genus (Reoviridae family) . It is vectored to vertebrates by Culicoides species and causes disease in certain ruminants, notably sheep.
  • the genome of BTV consists of 10 unique double-stranded (ds) RNA molecules, each believed to code for a single polypeptide product. (Gorman et al. , 1981; Sanger and Mertens, 1983).
  • the ten dsRNA species are contained in an inner core structure that contains five types of proteins, two that are major (VP3 and VP7) and three that are minor components (VPl, VP4 and VP6) .
  • the core is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5, to give a complete virion particle with a diameter of approximately 69 nm.
  • non-structural proteins In addition to the above-mentioned structural proteins, three non-structural proteins (NSI, NS2 and NS3) appear in BTV infected cells. Their function in the replication or morphogenesis of BTV is not known. Two viral specific entities, tubules and granular inclusion bodies, are routinely obserbed in BTV infected cells (Lecatsas, 1968) . These morphological structures are attached to the intermediate filament component of the cell's cytoskeleton (Eaton, B.T. et al. , 1988) and are presumed to be involved in the virus assembly process.
  • tubular structures are composed entirely of one type of polypeptide, namely the 64,000 Dalton (64 kD) NSI protein, which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
  • 64,000 Dalton (64 kD) NSI protein which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
  • M6 BTV dsRNA middle size segment No. 6
  • a process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide.
  • An example of such a polypeptide is the NSI protein of bluetongue virus.
  • insects and cultured insect cells are capable of producing bluetongue virus non- structural proteins in morphological forms which resemble structures observed in bluetongue-virus infected mammalian, cells.
  • BTV-NSI when produced in accordance with the invention in insect cells has been found to "self-assemble" into tubules which are similar to tubules observed in bluetongue virus infected sheep cells.
  • the expression vectors used in the method of the invention may comprise a recombinant baculovirus having a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein.
  • Such recombinant baculoviruses may include promoter systems native to naturally occurring baculoviruses, for example the so-called “polyhedrin” promoter, or they may include other promoter systems capable of directing expression of polypeptide in transformed insect or cultured insect cells.
  • Especially suitable cultured insect cells are those of Spodoptera f_vugipe ⁇ da.
  • antigenic form as used herein to refer to a protein is meant a protein which is capable of exhibiting an antigenic property of a native bluetongue virus protein, e.g. the capability of binding to an antibody to said protein.
  • BTV serotype 10 (BTV-10) NSI gene product using an expression system based on recombinant baculoviruses is illustrated by the following Example.
  • the expressed protein has been shown to be similar in size and antigenic properties to the authentic BTV NSI protein. It reacts with BTV ' antibody and forms numerous tubular structures in the cytoplasm of the infected insect cells. The tubular structures have been purified to homogeneity from infected cell extracts. Further the expressed polypeptide has been used to identify antibodies to five United States BTV serotypes in infected sheep sera, indicating the potential of the expressed protein as a group reactive antigen in the diagnosis of BTV infections.
  • Example the BTV-10 M6 gene product is expressed in an insect baculovirus expression vector derived from AcNV.
  • A. Viruses and cells United States prototype BTV-10 was plaque cloned using monolayers of BHK-21 cells. The viral dsRNA was purified as described by Yamaguchi et al. (1988) and the 10 individual RNA segments separated and isolated as described previously (Purdy et al. , 1984). AcNPV and recombinant baculovirus stocks were grown and assayed in confluent monolayers of S. fvugipe ⁇ da cells in medium containing 10 fetal calf serum according to the procedures described by Brown and Faulkner (1977) • Occasionally virus stocks were made using spinner cultures of these insect cells.
  • B DNA cloning of the BTV10-M6 RNA.
  • Polyadenylation of BTV-10 dsRNA and synthesis of cDNA copies of the polyadenylated M6 RNA using an oligo(dT) 1 _ 1 o primer were undertaken as described previously (Purdy et al. , 1984).
  • the RNA templates were removed by treatment with 0.5 M K0H and double-stranded DNA generated by self-annealing. The products were repaired using the Klenow large fragment of DNA polymerase, followed by 3' tailing with dC and annealing to Pstl-cut, dG-tailed, pBR322 plasmid DNA (Maniatis et al. , 1982).
  • RNA gel electrophoresis blotting and hybridization.
  • Purified BTV-10 RNA was resolved on an agarose gel, blotted onto a Genescreen membrane (New England Nuclear, Boston MA) and hybridized to nick- translated cloned DNA by procedures described previously (Purdy et al. , 1984).
  • Plasmid DNA manipulations were carried out following the procedures described by Maniatis and associates (Maniatis et al. , 1982) . Restriction enzymes, T4 DNA ligase and the Klenow large fragment of DNA polymerase, were purchased from New England Biolabs, Inc. (Beverly, MA) . Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (FGR) .
  • S. fvugipevda cells were transfected with mixtures of infectious AcNPV DNA and DNA obtained from plasmid pAcBTV 10-6. Recombinant viruses were obtained as described previously (Inumaru and Roy, 1987) . One of the derived recombinant viruses was designated AcBTV 10-6.
  • glycerol, 5% ⁇ -mercaptoethanol, 62.5 mM Tris-HCl, 0.01 bromophenol blue, pH 6.8) were added to each sample and the mixture heated at 100°C for 10 min.
  • Proteins were analysed by electrophoresis in a 10-30$ linear gradient polyacrylamide gel in the presence of SDS (SDS-PAGE) as described by Laemmli (1970) . After electrophoresis, the gel was stained with 0.25% Coomassie brilliant blue.
  • the membrane was soaked for 1 hr at room temperature in anti-rabbit IgG-goat IgG-alkaline phosphatase conjugate (Sigma Chemical Co.), also diluted in blocking buffer. After further washing with PBST, bound antibodies were detected by incubating using Fast BB salt and a-Naphthyl phosphate (Sigma Chemical Co.) as substrate.
  • PBST PBS
  • a solid phase indirect micro-ELISA was used to demonstrate the reactivity of recombinant AcBTV 10-6 antigen with various polyclonal BTV antisera.
  • S. fs gipexda cells infected 2 hr previously with recombinant AcBTV 10-6 virus (see above) were collected and subjected to freezing and thawing followed by low speed centrifugation to remove cellular debris.
  • the supernatant was diluted (1:10- to 1:10,000-fold) with sodium carbonate buffer (15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)-
  • sodium carbonate buffer 15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)
  • a 96-well polyvinylchloride microplate (Flow Laboratories) was coated overnight at 4xC with 50fl of the diluted antigen.
  • the plate was washed three times between each step of the following protocol by flooding the wells of the plate with PBST buffer.
  • the antigen-coated microplate was washed and blocked with blocking solution for 3 hr at room temperature.
  • BTV antisera were diluted (1:100- to 1:12,800-fold) in blocking solution and 50 ⁇ l of diluted sera were added to each well.
  • Cells were infected with the AcBTV 10-6 recombinant baculovirus and the infected cells harvested 4 or 5 days post-infection. The cells were recovered, washed twice with PBS and resuspended in 10 mM Tris-HCl (pH 7-4) and disrupted by sonication. The resulting cell extract was loaded oh a 10% to 50 (wt/v) sucrose gradient in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and centrifuged at 40,000 rpm for 3 hr using an SW4l rotor. After centrifugation, the gradient was fractionated and a portion of each fraction was subjected to gel electrophoresis. The peak fractions containing NSI protein were pooled and pelleted by centrifugation for 2 hr at 40,000 rpm. The pellet was resuspended in 10 mM Tris HC1 buffer (pH 7.4).
  • a plasmid (pBTV10-6) containing the complete BTV-10 M6 sequence was constructed from two overlapping clones as described above (Fig. 2) .
  • the restriction enzyme M ⁇ el was used to isolate the entire coding region of the M6 DNA (including 1 bases upstream from the ATG initiation codon and 59 bases downstream from the TAG stop codon) and the DNA used to prepare a recombinant baculovirus transfer vector.
  • the 60 kD protein was NSI
  • a sample of the AcBTV 10-6 infected cell extract was electrophoresed, transferred onto a Durapore membrane and subjected to Western analyses using anti-BTV-10 sera as described in Methods.
  • the 60 kD protein (lane c) was identified by the alkaline phosphatase conjugate detection procedure.
  • tubules of various lengths were evident. In cross-section, they exhibited a diameter of ca 60 nm. Many of the tubules appeared to contain ribosome-like particles (Fig. 5. R arrowheads). Both the structures and arrangement of the tubules were comparable to the tubular structures reported by others in BTV infected BHK-21 cells (Huismans and Els, 1979). As expected, polyhedra were only evident in the AcNPV infected cells (Fig. 5. P arrowheads).
  • Fibrous structures were observed both in AcNPV and in the recombinant virus infected cells (Fig. 5) • In the latter, the tubules appeared to be aligned along the edges of bundles of the fibrous material (Fig. 5c and d) . Both the tubules and the fiberous structures were randomly oriented with respect to one another. In some cells bundles of fibers were seen in both the nucleus and the cytoplasm (Fig. 5e, f) , with tubules mostly, but not exclusively associated with the cytoplasmic fibers. Fewer tubules were seen in the nuclei (Fig. f)• Whether these tubules were formed in the nucleus, or occurred there because the cell was in the terminal stage of infection, is not known.
  • Recombinant virus infected cell extracts were absorbed to microtiter plates (representing some 50 ng of NSI protein per well) and incubated with either polyclonal BTV-2, or BTV-10, or BTV-11, or BTV-13, or BTV-17 sheep antisera, or with normal sheep serum as a control.
  • the derived antigen-antibody complexes were detected by incubating with anti-sheep-alkaline phosphatase conjugates followed by the addition of an enzyme substrate.
  • Fig. 7 all five BTV antisera reacted with the recombinant antigen in proportion to the end point titer of the antisera. No reaction was detected with the normal sheep serum. No reactivity was obtained when each of the BTV antisera was tested with AcNPVinfected cell extracts.
  • NSI is the major viral protein synthesized in BTV-infected cells and is a major constituent of the tubules which are observed in such cells. (Huismans and Els, 1979). It has now unexpectedly been found that baculovirus expressed NSI protein also form tubules in insect cells. The two overlapping clones (#14 and 39) were used to construct a plasmid containing the complete gene (pBTV 10-6) . A recombinant baculovirus was prepared with the NSI gene sequences under the control of the AcNPV polyhedrin promoter. The data herein shows that the BTV NSI protein is expressed to a high level in insect cells infected with this recombinant baculovirus.
  • NSI, NS2 and NS3 can be used as group specific probes to detect the presence of bluetongue virus (all 24 serotypes); Ritter and Roy, 1988.
  • BTV 10 NSI antigen can be used to detect antibodies to the US strains (BTV-2, BTV-10, BTV-11, BTV-14 and BTV-17) ; Urakawa and Roy, 1988.
  • a culture of AcNPV-BTV-10 has been deposited at the European Collection of Animal Cell Cultures (ECACC) on 10th August 1989 under Accession No. 89081017.
  • Fig. 1 Strategy used to determine the sequences of cDNA clones of the BTV- 10 M6 gene. The distance and directions in which individual strands of two overlapping clones were sequenced are shown by the solid arrows. Restriction enzyme sites used are as follows: Ma, Mael; Hd, Hind l; R, HinfI; D, DdeI; Pv,PuuI; Ms, spI.
  • FIG. 2 Schematic diagram of the construction of the transfer vector pAcBTVlO-6.
  • a pBR332-based plasmid (pBTV 10-6) containing the entire coding region of the BTV-10 M6 DNA was constructed from two overlapping partial clones as described in Methods.
  • the complete clone (pBTV10-6) was used to construct the transfer vector (pAcBTVlO-6) as described in Methods.
  • the sequence of the 5' insertion site was determined by the method of Maxam and Gilbert (18) using a Hin ⁇ HL restriction fragment (BTV DNA residue #296).
  • Fig. 3 Hydropathic plot and distribution of cvsteine residues for the predicted M6 gene product of BTV-10.
  • the plot involves a span setting of 21 amino acids.
  • Fig.4 Expression of NSl protein bv recombinant baculoviruses derived from the pAcBTV10-6 transfer vector.
  • S. frugiperda cells were infected with recombinant (c) or wild type AcNPV (b). Proteins were recovered at 72 hr post-infection and an aliquot of each sample was resolved by gel electrophoresis. Uninfected cells were treated similarly (a). The resolved protein bands were either detected by staining with Coomassie brilliant blue (A), or blotted onto nitrocellulose membranes and detected immunolog ⁇ cally with a ti BTV-10 serum (B) as described in Methods. The positions of NSI and the AcNPV polyhedrin protein (P) are indicated. Molecular weights (in kD) are indicated on the left.
  • FIG. 5 Electron micrographs of NSl-derived tubules produced by S. frugiperda cells infected with recombinant viruses.
  • S. frugiperda cells infected with AcNPV (panel a), or a recombinant virus (panels b-f) were fixed with 2% glutaraldehyde 72 hr post-infection and processed for electron microscopy as described in Methods.
  • P polyhedrin
  • V virus particles
  • M mitochondria
  • R ribosomes
  • F fibrous structure
  • T tubules
  • N nuclear membrane.
  • FIG. 6 Three-dimensional arrangement of the tubules in the infected S. frugiperda cells.
  • A A series of representative virus (A-H) of the single arrays in a thin section of the tubules were photographed at 10° intervals of specimen tilt.
  • B A schematic three-dimensional interpretation of the structure are represented (a, b and c).
  • Fig. 7 Reaction of bluetongue antibodies to recombinant baculovirus derived antigen using indirect ELISA: Recombinant AcBTV 10-6 infected cell extracts were adsorbed to the solid phase and examined using 1:100 to 1:12800 dilutions of sheep anti-BTV-2 serum ( ⁇ e), or anti-BTV- 10 serum (o o), or anti-BTV-11 serum ( ⁇ A), or anti-BTV-13 serum ( ⁇ ⁇ ), or anti-BTV-17 serum (G ⁇ ), or with normal sheep serum (gg U).
  • Fig. 8 SDS-PAGE of purified NSI protein stained with Coomassie brilliant blue: AcBTV10-6 recombinant baculovirus infected cells were disrupted and tubules were recovered by sedimenting in sucrose gradient (10-50% w/v) centrifugation as described in Methods. The peak fractions containing NSl were pooled and subjected to SDS-PAGE analysis. The proteins recovered from unpurif ⁇ ed recombinant virus infected cells (1) are compared with NSl protein purified through sucrose gradient centrifugation (2). - /S

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On décrit des protéines non structurales du virus ci-décrit (notamment la protéine NSI du virus de la fièvre catarrhale) exprimées dans des cellules d'insectes.
PCT/GB1989/000939 1988-08-16 1989-08-15 Production de proteines non structurales du virus de la fievre catarrhale (btv) faisant appel a un vecteur d'expression du baculovirus WO1990002186A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8819453.5 1988-08-16
GB888819453A GB8819453D0 (en) 1988-08-16 1988-08-16 Production of bluetongue virus non-structural proteins using baculovirus expression vector

Publications (1)

Publication Number Publication Date
WO1990002186A1 true WO1990002186A1 (fr) 1990-03-08

Family

ID=10642209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1989/000939 WO1990002186A1 (fr) 1988-08-16 1989-08-15 Production de proteines non structurales du virus de la fievre catarrhale (btv) faisant appel a un vecteur d'expression du baculovirus

Country Status (5)

Country Link
EP (1) EP0431038A1 (fr)
AU (1) AU4198889A (fr)
GB (1) GB8819453D0 (fr)
WO (1) WO1990002186A1 (fr)
ZA (1) ZA896202B (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026254A2 (fr) * 2000-09-27 2002-04-04 The Uab Research Foundation Systeme d'apport de vaccin particulaire non replicatif et techniques de preparation et d'utilisation de ce systeme
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178435A2 (fr) * 1984-08-31 1986-04-23 Research Corporation Sonde cADN pour la détection du virus "langue bleue"
EP0279661A2 (fr) * 1987-02-19 1988-08-24 Oxford Virology Limited Production d'antigènes du virus de la langue bleue en utilisant un vecteur d'expression du type baculovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178435A2 (fr) * 1984-08-31 1986-04-23 Research Corporation Sonde cADN pour la détection du virus "langue bleue"
EP0279661A2 (fr) * 1987-02-19 1988-08-24 Oxford Virology Limited Production d'antigènes du virus de la langue bleue en utilisant un vecteur d'expression du type baculovirus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, Vol. 84, 1987, (Philadelphia, PA, US) H. HUISMANS et al.: "A Comparison of Different Cloned Bluetongue Virus Genome Segments as Probes for the Detection of Virus-Specified RNA" *see Abstracts 52328 & Virology, 158(2): 373-380, 1987* *
CHEMICAL ABSTRACTS, Vol. 106, No. 21, 25 May 1987, (Columbus, Ohio, US), S. INUMARU et al.: "Production and Characterization of the Neutralization Antigen VP2 of Bluetongue Virus Serotype 10 using a Baculovirus Expression Vector", see page 549* Abstract 174284t & Virology, 1987, 157(2), 472-9* *
J. Gen. Virol. , Vol. 67, 1986 SGM (GB) M.A. PURDY et al.: "Nucleotide Sequence of cDNA Clones Encoding the Outer Capsid Protein, VP5, of Bluetongue Virus Serotype 10", pages 957-962 *
J. Gen. Virol., Vol. 68, 1987, SGM (GB) S. INUMARU et al.: "Expression of Bluetongue Virus Group-Specific Antigen VP3 in Insect Cells by a Baculovirus Vector: its use for the Detection of Bluetongue Virus Antibodies" page 1627 *
Journal of Virology, Vol. 62, November 1988 American Soc. for Microbiology (US) T. URAKAWA et al.: "Bluetongue Virus Tubules made in Insect Cells by Recombinant Baculoviruses: Expression of the NS1 Gene of Bluetongue Virus Serotype 10" pages 3919-3927 *
Nucleic Acids Resaerch, Vol. 15, No. 17, 1987 IRL Press Ltd, Oxford, (GB) J. LEE et al.: "Complete Sequence of the NS1 Gene (M6 RNA) of Bluetongue Virus Serotype 10", page 7207 *

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026254A3 (fr) * 2000-09-27 2003-01-23 Uab Research Foundation Systeme d'apport de vaccin particulaire non replicatif et techniques de preparation et d'utilisation de ce systeme
WO2002026254A2 (fr) * 2000-09-27 2002-04-04 The Uab Research Foundation Systeme d'apport de vaccin particulaire non replicatif et techniques de preparation et d'utilisation de ce systeme
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8097702B2 (en) 2004-02-02 2012-01-17 Ambrx, Inc. Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US9260472B2 (en) 2004-02-02 2016-02-16 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8907064B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US8232371B2 (en) 2004-02-02 2012-07-31 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP2327724A2 (fr) 2004-02-02 2011-06-01 Ambrx, Inc. Polypeptides d'hormone de croissance humaine et leur utilisations
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
EP2284191A2 (fr) 2004-12-22 2011-02-16 Ambrx, Inc. Procédé de préparation de hGH
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US7846689B2 (en) 2004-12-22 2010-12-07 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7858344B2 (en) 2004-12-22 2010-12-28 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7883866B2 (en) 2004-12-22 2011-02-08 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US8143216B2 (en) 2004-12-22 2012-03-27 Ambrx, Inc. Modified human growth hormone
US7829310B2 (en) 2004-12-22 2010-11-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
US7947473B2 (en) 2004-12-22 2011-05-24 Ambrx, Inc. Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US7838265B2 (en) 2004-12-22 2010-11-23 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US7959926B2 (en) 2004-12-22 2011-06-14 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone mutants
US7736872B2 (en) 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
US8178494B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Modified human growth hormone formulations with an increased serum half-life
US8163695B2 (en) 2004-12-22 2012-04-24 Ambrx Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
EP2399893A2 (fr) 2004-12-22 2011-12-28 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
US8178108B2 (en) 2004-12-22 2012-05-15 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
WO2006069246A2 (fr) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides
US8093356B2 (en) 2005-06-03 2012-01-10 Ambrx, Inc. Pegylated human interferon polypeptides
US9488660B2 (en) 2005-11-16 2016-11-08 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US8053560B2 (en) 2006-09-08 2011-11-08 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
US8022186B2 (en) 2006-09-08 2011-09-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
US7919591B2 (en) 2006-09-08 2011-04-05 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8618257B2 (en) 2006-09-08 2013-12-31 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US10961291B2 (en) 2007-03-30 2021-03-30 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8383365B2 (en) 2007-03-30 2013-02-26 Ambrx, Inc. Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US10377805B2 (en) 2007-03-30 2019-08-13 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9975936B2 (en) 2007-03-30 2018-05-22 Ambrx, Inc. Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9517273B2 (en) 2007-03-30 2016-12-13 Ambrx, Inc. Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US11993637B2 (en) 2007-03-30 2024-05-28 Ambrx, Inc. Modified FGF-21 polypeptides with non-naturally encoded amino acids
US9079971B2 (en) 2007-03-30 2015-07-14 Ambrx, Inc. Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
EP3225248A1 (fr) 2008-07-23 2017-10-04 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US8278418B2 (en) 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
US10428333B2 (en) 2008-09-26 2019-10-01 Ambrx Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
WO2010037062A1 (fr) 2008-09-26 2010-04-01 Ambrx, Inc. Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels
US8569233B2 (en) 2008-09-26 2013-10-29 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9121025B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
US9644014B2 (en) 2008-09-26 2017-05-09 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (fr) 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
US9156899B2 (en) 2008-09-26 2015-10-13 Eli Lilly And Company Modified animal erythropoietin polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
US9962450B2 (en) 2010-08-17 2018-05-08 Ambrx, Inc. Method of treating heart failure with modified relaxin polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US10253083B2 (en) 2010-08-17 2019-04-09 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP4302783A2 (fr) 2010-08-17 2024-01-10 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US11786578B2 (en) 2010-08-17 2023-10-17 Ambrx, Inc. Modified relaxin polypeptides and their uses
US8735539B2 (en) 2010-08-17 2014-05-27 Ambrx, Inc. Relaxin polypeptides comprising non-naturally encoded amino acids
US9452222B2 (en) 2010-08-17 2016-09-27 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US10702588B2 (en) 2010-08-17 2020-07-07 Ambrx, Inc. Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US10751391B2 (en) 2010-08-17 2020-08-25 Ambrx, Inc. Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US11439710B2 (en) 2010-08-17 2022-09-13 Ambrx, Inc. Nucleic acids encoding modified relaxin polypeptides
US11311605B2 (en) 2010-08-17 2022-04-26 Ambrx, Inc. Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US11248031B2 (en) 2014-10-24 2022-02-15 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US9631004B2 (en) 2014-10-24 2017-04-25 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10377806B2 (en) 2014-10-24 2019-08-13 Bristol-Myers Squibb Company Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US10189883B2 (en) 2014-10-24 2019-01-29 Bristol-Myers Squibb Company Therapeutic uses of modified FGF-21 polypeptides
US11185570B2 (en) 2017-02-08 2021-11-30 Bristol-Myers Squibb Company Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en) 2017-02-08 2022-06-21 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof

Also Published As

Publication number Publication date
EP0431038A1 (fr) 1991-06-12
ZA896202B (en) 1990-08-29
AU4198889A (en) 1990-03-23
GB8819453D0 (en) 1988-09-21

Similar Documents

Publication Publication Date Title
WO1990002186A1 (fr) Production de proteines non structurales du virus de la fievre catarrhale (btv) faisant appel a un vecteur d'expression du baculovirus
Urakawa et al. Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10
Belyaev et al. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells
French et al. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV
DE3751092T2 (de) Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.
EP0554414A1 (fr) Procede de production d'un vaccin sous-unitaire contre le parvovirus canin et autres virus apparentes
Roy et al. Identification of bluetongue virus VP6 protein as a nucleic acid-binding protein and the localization of VP6 in virus-infected vertebrate cells
WO1990010078A1 (fr) Systeme ameliore d'expression de baculovirus capable de produire des proteines de genes etrangers en grande quantite
JPH0586088A (ja) ニワトリ貧血ウイルスワクチン及び診断法
Le Blois et al. Synthesis and characterization of chimeric particles between epizootic hemorrhagic disease virus and bluetongue virus: functional domains are conserved on the VP3 protein
DE69019359T2 (de) Menschliche parvovirus-b19-proteine und virusähnliche partikeln, deren herstellung sowie deren verwendung in diagnostischen tests und in impfstoffen.
JPH0365191A (ja) スフェロイジン単離ｄｎａおよび組み換え昆虫ポックスウィルス発現ベクター
AP114A (en) Production of bluetongue virus antigens using a baculovirus expression vector.
Taylor et al. Transient expression and mutational analysis of the rotavirus intracellular receptor: the C-terminal methionine residue is essential for ligand binding
DE3382718T2 (de) Peptide, die eine Immunogen-Lage des Poliovirus des Sabin-Stammes enthalten.
KR100224331B1 (ko) 조환수두 대상포진바이러스 및 그 제작방법
US6379885B1 (en) Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines
EP0284791B1 (fr) Molécules d'ADN et d'ARN du virus de la méningoencéphalite du printemps précoce sous-type de l'ouest, polypeptides codés par celles-ci ainsi que leur utilisation
JPH02501114A (ja) 蛋白質合成用発現ベクター及びかゝるベクター構成に使用するプラスミドレプリコン及び配列カセット
Monastyrskaya et al. Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein
AU667796B2 (en) Production of antigens by self-assembly of polypeptide components
US5686270A (en) Production of antigens by self-assembly of polypeptide components
Nel et al. A comparison of different cloned genome segments of epizootic haemorrhagic disease virus as serogroup-specific probes
Brun et al. The relationship of Piry virus to other vesiculoviruses: a re-evaluation based on the glycoprotein gene sequence
US5833995A (en) Use of bluetongue virus proteins as vaccine components

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989909839

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989909839

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989909839

Country of ref document: EP